Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 4, 2025 • 11:00 AM ET

Date/Time Source News Release
12/16/2024 09:15 AM EST PR Newswire Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
11/20/2024 09:29 AM EST PR Newswire Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
11/05/2024 09:29 AM EST PR Newswire Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
10/31/2024 09:29 AM EDT PR Newswire Genprex to Participate in 2024 BIO Europe Conference
10/28/2024 09:29 AM EDT PR Newswire Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma
10/24/2024 09:29 AM EDT PR Newswire Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive
10/15/2024 09:29 AM EDT PR Newswire Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
10/10/2024 09:29 AM EDT PR Newswire Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
10/07/2024 09:29 AM EDT PR Newswire Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
09/23/2024 09:29 AM EDT PR Newswire Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes
Page

Additional News

As of January 4, 2025 • 11:00 AM ET

Date/Time Source News Release
11/23/2024 04:40 AM EST US Earnings Reports Expected earnings - Genprex Inc.
10/28/2024 04:30 PM EDT QM US Market Movers News US Companies Moving the Markets, Evening edition
Mon, Oct 28, 2024 as of 4:00 pm ET
10/23/2024 10:00 AM EDT QM US Market Movers News US Companies Moving the Markets, Morning edition
Wed, Oct 23, 2024 as of 10.00 am ET
10/22/2024 04:30 PM EDT QM US Market Movers News US Companies Moving the Markets, Evening edition
Tue, Oct 22, 2024 as of 4:00 pm ET
10/22/2024 11:11 AM EDT InvestorBrandNetwork Genprex Inc. (NASDAQ: GNPX) is One of Tuesday Morning's Most Active Stocks
10/22/2024 10:01 AM EDT QM US Market Movers News US Companies Moving the Markets, Morning edition
Tue, Oct 22, 2024 as of 10.00 am ET
10/21/2024 04:30 PM EDT QM US Market Movers News US Companies Moving the Markets, Evening edition
Mon, Oct 21, 2024 as of 4:00 pm ET
10/21/2024 02:42 PM EDT 24/7 Market News The MoBot Report
10/21/2024 10:00 AM EDT QM US Market Movers News US Companies Moving the Markets, Morning edition
Mon, Oct 21, 2024 as of 10.00 am ET
08/14/2024 02:27 PM EDT SeekingAlpha Genprex stock slides 14% following Reqorsa study updates
Page